The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
Fresh Insights Into the Practicalities of Developing Biosimilar Biologics
Posted 01 October 2009 | By
Biotech products coming off patent afford a window of opportunity to obtain a marketing approval for a "follow-on biologic" by a new product developer. If the supporting data are sufficient to authorize interchangeability and substitution, the new product is defined as a similar biologic or "biosimilar." Europe is leading the way in defining the regulatory pathway for biosimilars. This article shares lessons learned that can provide strategic insights to guide biosimilar development plans.